Free Trial
NASDAQ:ELAB

Elevai Labs (ELAB) Stock Price, News & Analysis

Elevai Labs logo
$0.02
-0.01 (-33.22%)
(As of 11/4/2024 ET)

About Elevai Labs Stock (NASDAQ:ELAB)

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.03
$0.35
52-Week Range
$0.02
$4.24
Volume
253.24 million shs
Average Volume
10.00 million shs
Market Capitalization
$418,180.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Elevai Labs Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

ELAB MarketRank™: 

Elevai Labs scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevai Labs is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevai Labs is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elevai Labs has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Elevai Labs' valuation and earnings.
  • Percentage of Shares Shorted

    11.28% of the float of Elevai Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevai Labs has recently increased by 172.44%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elevai Labs does not currently pay a dividend.

  • Dividend Growth

    Elevai Labs does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.28% of the float of Elevai Labs has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevai Labs has recently increased by 172.44%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Elevai Labs has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Elevai Labs this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for ELAB on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevai Labs insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    37.00% of the stock of Elevai Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.22% of the stock of Elevai Labs is held by institutions.

  • Read more about Elevai Labs' insider trading history.
Receive ELAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter.

ELAB Stock News Headlines

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Elevai Biosciences highlights past preclinical data on EL-32
See More Headlines

ELAB Stock Analysis - Frequently Asked Questions

Elevai Labs' stock was trading at $1.8282 at the beginning of the year. Since then, ELAB shares have decreased by 98.9% and is now trading at $0.0201.
View the best growth stocks for 2024 here
.

Elevai Labs, Inc. (NASDAQ:ELAB) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.08) EPS for the quarter. The firm earned $0.61 million during the quarter. Elevai Labs had a negative trailing twelve-month return on equity of 216.19% and a negative net margin of 191.96%.

Elevai Labs (ELAB) raised $6 million in an initial public offering (IPO) on Tuesday, November 21st 2023. The company issued 1,500,000 shares at a price of $4.00 per share. Univest Securities acted as the underwriter for the IPO.

Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII).

Company Calendar

Last Earnings
8/14/2024
Today
11/04/2024
Next Earnings (Estimated)
12/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELAB
Previous Symbol
NASDAQ:ELAB
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Net Income
$-4,300,000.00
Net Margins
-191.96%
Pretax Margin
-191.92%

Debt

Sales & Book Value

Annual Sales
$2.47 million
Book Value
$0.22 per share

Miscellaneous

Free Float
13,107,000
Market Cap
$418,180.50
Optionable
N/A
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:ELAB) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners